GRI GRI Bio, Inc.

AMX
$1.67

GRI Bio, Inc. (GRI) is expected to report earnings on November 13, 2026, before the market open. The consensus earnings estimate is a loss of $1.08 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of -8.2% since its last earnings release on August 14, 2026.

GRI Bio Beat Consensus Estimates
Earnings Date
3rd Quarter, Sep 2026
Nov 13
Friday · 8:35 AM ET
Earnings Whisper
-
vs ($1.08)
Volatility
Enter your expectations below to reveal the current volatility.
Trend Analysis
Expectation
Earnings
Price action
Signals
Score
Sentiment
Grade
Life Cycle
Call Analysis
Earnings-AVWAP $2.09

Sign in or subscribe to unlock sentiment, short interest, and technical indicators.

About GRI Bio, Inc.

GRI Bio Inc. is a clinical stage biopharmaceutical company which focused on fundamentally changing the way inflammatory, fibrotic and autoimmune diseases are treated. GRI Bio Inc., formerly known as Vallon Pharmaceuticals Inc., is based in PHILADELPHIA, PA.

Sector

Healthcare

Industry

Biotechnology